PrematurityPhase 4lactoprenewNCT01172236
Supplementation With Lactoferrin in Preterm Newborns
A Phase 4 study testing Lactoferrin in people with Prematurity and Low Birth Weight, run by University of Siena.
Trial summary
The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done through the assessment of neuro-developmental follow-up. Read more about this study
- Who is it for?
- Ages 23 to 32 weeks
- Conditions the study is for
- Prematurity, Low Birth Weight
- What is being tested?
- Lactoferrin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,300 participants
- Where
- No sites listed yet
- Study dates
- Jan 2011to Jan 2013
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 to 32 weeks
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Newborns with a birthweight ≤ 1500 grand/or gestational age ≤ 32 weeks
- Sign of the informed consent by parents
Who cannot join
- Fetal-onset disorders and/or recognizable at birth
- Milk intolerance
- Family history of allergies
- Use of infant formula supplemented with lactoferrin
About this study
The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done through the assessment of neuro-developmental follow-up.
The secondary objective is to identify a panel of markers for assessing oxidative stress and for a correlation with the lactoferrin antioxidant effect.
Read the detailed description
The study arises from the need to structure care to identify a product natural with antioxidant propriety that may reduce the extent of damage in perinatal neurological disorders related to oxidative stress by limiting the pain for infants and families and simultaneously reducing the cost to the SSN arising from standard pharmacological therapy and rehabilitation in the short and medium term. The research results will remain available to the scientific community and will not be used for profit or commercial. The iron (Fe) is the most abundant transition metal1 in the body and an essential element for growth and welfare of almost all life2 where he played a key role in many biochemical processes3. It is essential as cofactor in many enzymatic reactions and as catalyst in the processes of electron transport, yet is potentially toxic and rarely available. In the presence of oxygen Fe causes harmful action on the cell since it enhances the production by non-enzymatic reactive oxygen species. The hydroxyl radical in particular, can damage various cellular components such as DNA, proteins and membrane lipids. All bodies have therefore developed strategies that allow them to retain Fe was acquired in a soluble, nontoxic and in a form readily available. The Fe excess, also caused by weak bonds that the metal has with nonspecific and specific plasma proteins may carry out its negative effects by generating free radicals through the reactions of Fenton and Heber-Weiss4. Physiological requirements of Fe is higher during periods of rapid growth and differentiation, such as perinatal and nervous system that develops rapidly in late fetal life and early neonatal period, appears to be particularly sensitive to modulations of Fe contents5 In the newborn the inability to regulate, as necessary, the uptake of Fe by the immature gut may be the reason for failure and / or excess metal. Both situations may have adverse effects on neurological development of infants and in case of failure becomes irreversible even6-8 because any supplementation does not improve autcome9-11. In both cases the events that occur in early childhood have adverse effects on neuronal function in adults. The mechanism by which iron deficiency affects brain development is completely unknown but we know that can range up to a general lack metabolic errors of myelination and synaptogenesis and changes in specific funcions12 . It was also suggested that the adverse clinical outcomes in premature infants receiving blood transfusions and / or colonization13 may be related to oxidative damage14-17 <br>The main source of food for newborns is breast milk or formula. Breast milk contains heme Fe consequently the non-heme Fe, which is bound to milk proteins and other substances with lower molecular weight, is the main source of Fe in the diet of infants. The child is able to regulate the absorption of iron from the gut, in response to supplementation, only near the first year of life,18 so the inability of infants to regulate the intestinal absorption predisposes them to a deficiency when the Fe in the diet is insufficient, or an overload, when levels in the diet are high. It was also suggested that the enrichment of Fe in young children may lead to an increase in its plasma concentration and the formation of nonspecific compounds (nonspecific binding to proteins with low affinity bonds) that give rise to the so-called free Fe (NPBI) which originate from reactive oxygen species. Some authors have demonstrated increased oxidative stress in infants of very low birth weight who were subjected to a large oral iron supplementation, especially if breastfed seno.19-21 Although gestational age and some clinical treatments such as transfusions and ventilation considered because of an increased risk of oxidative damage Fe-indotto.22 Since the status of Fe in breast-fed term infants is usually satisfactory, at least until the sixth month, and an important part of Fe in human milk is bound to lactoferrin, has been previously suggested that the effect protective of human milk is related to the presence of this protein fixing most of the Fe and regulates its absorption. The lactoferrin is an iron-binding protein, naturally found in high concentrations in breast milk and in low concentrations in other fluids esocrini23. For the size and structure of lactoferrin is closely linked to another group of Fe-related protein, the transferrin and is considered by many as a member of this family. Lactoferrin binds iron with high affinity binding and its structure is unusually resistant to proteolytic degradation. Besides regulating the absorption of iron during inflammatory processes and infettivi24 performs several physiological functions including antibacterial, antifungal, antivirale25, antiparassitary26, antitumoral27, immunomodulator28-29. This ability antibacterial and antiviral properties, may explain the low prevalence and shorter duration of infection in breast-fed infants. In human milk lactoferrin plays an antioxidant sequestering free ions of Fe30 and thus preventing lipid peroxidation and subsequent milk oxidation31. Some AA.32 have shown this property in vitro using salts and Fe ions in the presence of a biological agent such as reducing ascorbato33. A recent study has also demonstrated its antioxidant effect in blood34. Again lactoferrin is able to bind free Fe, from binding studies, avoiding be sure to trigger a series of chain reactions that produce free radicals and thus reduces the damage induced by oxidative stress. This explains why breastfed children have significantly higher total antioxidant capacity and significantly lower index of oxidative stress. A recent study on infants supplied with formula supplemented with lactoferrin showed that presence of this protein helps the absorption of Fe in the small gut. The same study suggests that its activity could stimulate the proliferation and differentiation of mucosal cells in the gut35, thus increasing the surface and in turn increase the absorption of nutrients. Studies in pregnancy women 36 suggests that lactoferrin may have an anti-inflammatory effect, while also improving the Fe status of women.
- Conditions
- Prematurity, Low Birth Weight
- Being tested
- Lactoferrin
- Medical subject headings
- Premature Birth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LactoferrinDrug
Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.
Control group: newborns (group B) will receive only standard therapy and they will be used as controls.
LactoferrinDrug
Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
| Study group | Role | What they receive |
|---|---|---|
| Lactoferrin | Experimental | Not described Receives: Drug: Lactoferrin |
What is being measured
The primary outcome is the main question the study is designed to answer.
The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done trough the assessment of neuro-developmental follow-up.
Measured: 12 months
Secondary outcomes (1)
The secondary objective is to identify a panel of markers for assessing oxidative stress and for a correlation with the lactoferrin antioxidant effect.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jul 2010 (estimated)
- Study startJan 2011
- Primary completionJan 2012
- Study completionJan 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PrematurityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,300 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Siena
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Giuseppe Buonocore, University of Siena
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01172236
- Sponsor's protocol ID
- NEO-LF100-2010
- Acronym
- lactoprenew
- Status last verified
- Apr 2010
- First submitted
- 28 Jul 2010
- Last updated
- 26 Mar 2020
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Supplementation With Lactoferrin in Preterm Newborns
- ClinicalTrials.gov ID
- NCT01172236
- Acronym / sponsor ID
- lactoprenew / NEO-LF100-2010
- Conditions
- Prematurity, Low Birth Weight
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,300 participants (actual)
- Lead sponsor
- University of SienaUniversity, hospital or other
- Study start
- Jan 2011 (actual)
- Primary completion
- Jan 2012 (actual)
- Study completion
- Jan 2013 (actual)
- First posted
- 29 Jul 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done through the assessment of neuro-developmental follow-up.
The secondary objective is to identify a panel of markers for assessing oxidative stress and for a correlation with the lactoferrin antioxidant effect.
Detailed description
The study arises from the need to structure care to identify a product natural with antioxidant propriety that may reduce the extent of damage in perinatal neurological disorders related to oxidative stress by limiting the pain for infants and families and simultaneously reducing the cost to the SSN arising from standard pharmacological therapy and rehabilitation in the short and medium term. The research results will remain available to the scientific community and will not be used for profit or commercial. The iron (Fe) is the most abundant transition metal1 in the body and an essential element for growth and welfare of almost all life2 where he played a key role in many biochemical processes3. It is essential as cofactor in many enzymatic reactions and as catalyst in the processes of electron transport, yet is potentially toxic and rarely available. In the presence of oxygen Fe causes harmful action on the cell since it enhances the production by non-enzymatic reactive oxygen species. The hydroxyl radical in particular, can damage various cellular components such as DNA, proteins and membrane lipids. All bodies have therefore developed strategies that allow them to retain Fe was acquired in a soluble, nontoxic and in a form readily available. The Fe excess, also caused by weak bonds that the metal has with nonspecific and specific plasma proteins may carry out its negative effects by generating free radicals through the reactions of Fenton and Heber-Weiss4. Physiological requirements of Fe is higher during periods of rapid growth and differentiation, such as perinatal and nervous system that develops rapidly in late fetal life and early neonatal period, appears to be particularly sensitive to modulations of Fe contents5 In the newborn the inability to regulate, as necessary, the uptake of Fe by the immature gut may be the reason for failure and / or excess metal. Both situations may have adverse effects on neurological development of infants and in case of failure becomes irreversible even6-8 because any supplementation does not improve autcome9-11. In both cases the events that occur in early childhood have adverse effects on neuronal function in adults. The mechanism by which iron deficiency affects brain development is completely unknown but we know that can range up to a general lack metabolic errors of myelination and synaptogenesis and changes in specific funcions12 . It was also suggested that the adverse clinical outcomes in premature infants receiving blood transfusions and / or colonization13 may be related to oxidative damage14-17 <br>The main source of food for newborns is breast milk or formula. Breast milk contains heme Fe consequently the non-heme Fe, which is bound to milk proteins and other substances with lower molecular weight, is the main source of Fe in the diet of infants. The child is able to regulate the absorption of iron from the gut, in response to supplementation, only near the first year of life,18 so the inability of infants to regulate the intestinal absorption predisposes them to a deficiency when the Fe in the diet is insufficient, or an overload, when levels in the diet are high. It was also suggested that the enrichment of Fe in young children may lead to an increase in its plasma concentration and the formation of nonspecific compounds (nonspecific binding to proteins with low affinity bonds) that give rise to the so-called free Fe (NPBI) which originate from reactive oxygen species. Some authors have demonstrated increased oxidative stress in infants of very low birth weight who were subjected to a large oral iron supplementation, especially if breastfed seno.19-21 Although gestational age and some clinical treatments such as transfusions and ventilation considered because of an increased risk of oxidative damage Fe-indotto.22 Since the status of Fe in breast-fed term infants is usually satisfactory, at least until the sixth month, and an important part of Fe in human milk is bound to lactoferrin, has been previously suggested that the effect protective of human milk is related to the presence of this protein fixing most of the Fe and regulates its absorption. The lactoferrin is an iron-binding protein, naturally found in high concentrations in breast milk and in low concentrations in other fluids esocrini23. For the size and structure of lactoferrin is closely linked to another group of Fe-related protein, the transferrin and is considered by many as a member of this family. Lactoferrin binds iron with high affinity binding and its structure is unusually resistant to proteolytic degradation. Besides regulating the absorption of iron during inflammatory processes and infettivi24 performs several physiological functions including antibacterial, antifungal, antivirale25, antiparassitary26, antitumoral27, immunomodulator28-29. This ability antibacterial and antiviral properties, may explain the low prevalence and shorter duration of infection in breast-fed infants. In human milk lactoferrin plays an antioxidant sequestering free ions of Fe30 and thus preventing lipid peroxidation and subsequent milk oxidation31. Some AA.32 have shown this property in vitro using salts and Fe ions in the presence of a biological agent such as reducing ascorbato33. A recent study has also demonstrated its antioxidant effect in blood34. Again lactoferrin is able to bind free Fe, from binding studies, avoiding be sure to trigger a series of chain reactions that produce free radicals and thus reduces the damage induced by oxidative stress. This explains why breastfed children have significantly higher total antioxidant capacity and significantly lower index of oxidative stress. A recent study on infants supplied with formula supplemented with lactoferrin showed that presence of this protein helps the absorption of Fe in the small gut. The same study suggests that its activity could stimulate the proliferation and differentiation of mucosal cells in the gut35, thus increasing the surface and in turn increase the absorption of nutrients. Studies in pregnancy women 36 suggests that lactoferrin may have an anti-inflammatory effect, while also improving the Fe status of women.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lactoferrin | Experimental | Drug: Lactoferrin |
Who may qualify
- Ages
- 23 to 32 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Newborns with a birthweight ≤ 1500 grand/or gestational age ≤ 32 weeks
- Sign of the informed consent by parents
Key exclusion criteria (4 listed)
- Fetal-onset disorders and/or recognizable at birth
- Milk intolerance
- Family history of allergies
- Use of infant formula supplemented with lactoferrin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LactoferrinExperimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy. Control group: newborns (group B) will receive only standard therapy and they will be used as controls. | Drug | Lactoferrin |
| LactoferrinExperimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls. | Drug | Lactoferrin |
Primary outcome
The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done trough the assessment of neuro-developmental follow-up.
Time frame: 12 months
1 secondary outcome
The secondary objective is to identify a panel of markers for assessing oxidative stress and for a correlation with the lactoferrin antioxidant effect.
Time frame: 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Mar 2020.
Related trials for Prematurity
Enrolling by invitationObservational study
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
Acute Kidney Injury, Fluid Overload
RecruitingObservational study
Characterization of Diseases With Salivary Gland Involvement
Healthy Volunteer, Sjogren's Syndrome
Not yet recruiting
Strap To Reduce Apnea in Preterm Infants: A Randomized Crossover Trial
Apnea of Prematurity, Intermittent Hypoxemia
Active, not recruitingObservational study
Effects of Transitional Circulation in ELBW Infants
Neonatal Prematurity, Hypotension
Recruiting
Ventilator Pressure and Optimization of Compliance and Hemodynamics
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Lactoferrin in people with Prematurity and Low Birth Weight, run by University of Siena.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The main objective of the study is to evaluate the antioxidant effect of lactoferrin and its ability to reduce free radicals related diseases in the newborn. This evaluation will be done trough the assessment of neuro-developmental follow-up. (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2020; AzTrials last refreshed its copy on 30 Oct 2026.